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Background: Cognitive impairments are seen in first psychotic episode (FEP) patients. The neurobiological
underpinnings that might underlie these changes remain unknown. The aim of this study is to investigate whether
Brain Derived Neurotrophic Factor (BDNF) levels are associated with cognitive impairment in FEP patients compared
with healthy controls.
Methods: 45 FEP patients and 45 healthy controls matched by age, gender and educational level were selected
from the Basque Country area of Spain. Plasma BDNF levels were assessed in healthy controls and in patients. A
battery of cognitive tests was applied to both groups, with the patients being assessed at 6 months after the acute
episode and only in those with a clinical response to treatment.
Results: Plasma BDNF levels were altered in patients compared with the control group. In FEP patients, we
observed a positive association between BDNF levels at six months and five cognitive domains (learning ability,
immediate and delayed memory, abstract thinking and processing speed) which persisted after controlling for
medications prescribed, drug use, intelligence quotient (IQ) and negative symptoms. In the healthy control group,
BDNF levels were not associated with cognitive test scores.
Conclusion: Our results suggest that BDNF is associated with the cognitive impairment seen after a FEP. Further
investigations of the role of this neurotrophin in the symptoms associated with psychosis onset are warranted.
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Cognitive deficits have been described in patients with
psychotic illnesses. More specifically, studies have found
alterations in executive functioning, verbal memory and
attention from the onset of psychosis [1,2]. Although the
presence of these cognitive deficits is evident during the
acute episode, it has also been established that patients
diagnosed with chronic schizophrenia or bipolar dis-
order continue to have cognitive deficits [3].
Brain-Derived Neurotrophic Factor (BDNF) is a neuro-
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distribution, and reproduction in any mediumdiseases, such as depression [4], Alzheimer’s disease [5]
and psychotic disorders [6,7]. BDNF is highly expressed
in the cerebral cortex and hippocampus, brain areas
known to regulate functions such as memory and emo-
tion [6]. There is a correlation between hippocampal
volumes and serum BDNF levels, such that smaller
hippocampal volumes in drug-naïve patients with first
episode psychosis are associated with lower BDNF levels
[8]. A genetic interference of BDNF secretion could lead
to deficits in cognition [5]. BDNF genetic polymorph-
isms have been associated with volume reductions in the
central nervous system (CNS), such as smaller temporal
and occipital lobar gray matter volumes [9,10] and ab-
normal hippocampal activation [11]. Previous research
has found an association between BDNF Val66Met poly-
morphism and cognition: schizophrenic patients who areentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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spatial/constructional impairment [10,12], and BDNF
met carriers with bipolar disorder have a specific alter-
ation in executive function [13]. Preclinical investiga-
tions in animals indicate that BDNF promotes long-term
potentiation [14]. Some studies in first-episode psychosis
patients found that pharmacological treatment with
olanzapine [15] or aripiprazole [16] is associated with
increased BDNF levels. A recent clinical study has
shown that bipolar patients who respond well to lithium
treatment perform better in a battery of neuropsycho-
logical tests and have higher BDNF plasma levels than
patients with a poor response to lithium and are similar
to healthy controls [17]. A recent review of serum BDNF
levels in patients with a first psychotic episode shows a
significant decrease in patients with schizophrenia but
not in those with non-schizophrenia psychosis [18]. It is
thought that the measurement of peripheral markers, in-
cluding BDNF, may increase our understanding of
neuropsychiatric disorders [19-21].
To date, there is a lack of information about the rela-
tionship between BDNF levels and neurocognitive per-
formance in patients with a first psychotic episode.
Some animal studies [22] have suggested there could be
a positive correlation between BDNF levels in the brain
(especially the frontal cortex and hippocampus) and
those in plasma, supporting the use of plasma BDNF
levels as a biomarker of brain BDNF levels.
We investigated whether plasma BDNF levels are asso-
ciated with cognitive impairment in patients with a first
psychotic episode. We hypothesized a priori that plasma
BDNF levels would be positively associated with cogni-




Between 2003 and 2005, 47 Caucasian patients with a
first episode psychosis were recruited to the study while
they were inpatients in the acute phase of illness and
were followed up for 6 months. Participants were from
the Alava catchment area in Spain and gave written
informed consent to participate in protocols approved
by the Basque Country Ethical Committee.
Inclusion criteria for patients were: age between 18
and 50 years at the time of first evaluation; and contact
with mental health services for the first time with a diag-
nosis in the schizophrenia spectrum or a mood disorder
with psychotic symptoms as defined by DSM-IV [23].
Patients were excluded if they had psychotic symptoms
lasting longer than 6 months from inception to the time
they were assessed for study eligibility. Other exclusion
criteria were: presence of a concomitant Axis I disorder,
with the exception of drug or alcohol abuse; mentalretardation if functioning was impaired prior to onset of
the disorder; pervasive developmental disorders; neuro-




Psychiatric diagnoses were made by two clinical psychia-
trists at baseline (i.e. upon hospitalisation for the acute
episode) using the Structured Clinical Interview for
DSM-IV-Axis I [24]. The diagnoses were subsequently
reviewed and revised at the 6-month follow-up assess-
ment and the 6-month diagnoses were used to describe
the patients. Pharmacological treatment was prescribed
according to the usual practice of the psychiatrist.
Patients were clinically assessed at baseline and at
6 months after the acute episode using the Positive and
Negative Symptom Scale (PANSS) [25], the 21-item
Hamilton Depression rating scale (HAMD-21) [26] and
the Addiction Severity Index (ASI) [27] for use of drugs
and alcohol. Drug and alcohol use was then assigned
into one of 4 categories (no use, use, abuse, and depend-
ence) following the criteria described in a previous study
[28]. For describing the sociodemographic characteristics
of participants (Table 1), the 4 categories were re-
grouped into either use or no use.
Cognitive assessments at 6 months were only made on
patients who met the pre-established criteria for cognitive
evaluation, which was clinical recovery from the acute epi-
sode. The clinical team decided whether patients had
recovered from their psychotic symptoms and were ready
for cognitive evaluation by evaluating symptom severity
during patient interview and from the scores on the
PANSS positive symptom subscale (less than 4 in any
item) and HAMD-21 (less than 7 in the total score).
Consequently, two patients were considered not to be
clinically recovered at 6 months and, thus, were excluded
from the study.
Forty-five Caucasian healthy controls selected from
the same catchment area were matched by age, gender
and educational level to the patient sample. Control sub-
jects were not on medication, did not abuse alcohol, did
not use drugs, had no personal history of major psychi-
atric disorders, and had no major psychiatric disorders
in their first-degree relatives. The healthy controls were
clinically assessed once using the Structured Clinical
Interview for DSM-IV-Axis I [24].
Cognitive assessments
A battery of cognitive tests was administered to the
healthy controls and to the patients at 6 months after
the acute episode when they had responded to anti-
psychotic treatment. The cognitive domains assessed
were: immediate and delayed memory and learning
Table 1 Sociodemographic characteristics of the first






Age, median (SD) 24.3 (8.5) 24.0 (8.8) −0.146 0.884
Marital status, n (%)
Single 41 (91.1) 39 (86.7) 6.621 0.036
Married 1 (2.2) 6 (13.3)
Divorced 3 (6.7) 0 (0)
Years of education, n (%)
Primary 5 (11.1) 4 (8.9) 3.401 0.334
Obligatory 18 (40) 11 (24.4)
Secondary 16 (35.6) 24 (53.3)
University 6 (13.3) 6 (13.3)
Employment, n (%)
Student 14 (31.1) 27 (60) 13.425 0.004
Unemployed 14 (31.1) 5 (11.1)
Working 12 (26.7) 0 (0)
Sick leave 5 (11.1) 13 (28.9)
Diagnosis, n (%)
Schizophrenia 25 (55.6)
Affective disorder 12 (26.7)
Non specific psychosis 8 (17.8)
Drug use, n (%) yes
Tobacco 29 (64.4) 8 (17.8) 20.240 <0.001
Alcohol 30 (66.7) 16 (35.6) 8.715 0.003
Cannabis 22 (48.9) 3 (6.7) 19.994 <0.001
Other drugs 13 (28.9) 0 (0) 15.195 <0.001
Education: Primary (3–6 years), Obligatory (6–16 years), Secondary
(16–18 years), University (18–23 years).
SD Standard deviation.
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Memory and Verbal Paired Associates); working memory
and executive function using the Fluency Assessment
Scale, Trail Making Test B [30], Letter-Number Sequen-
cing and Digits backward (Wechsler Adult Intelligence
Scale, WAIS-III) [31], the interference score from the
Stroop Test [32] and using the Wisconsin Card Sorting
Test (WCST) [33]; intelligence (abstract reasoning and
crystallized intelligence) using Similarities and Vocabu-
lary (WAIS-III) [31]; attention and processing speed
using Digits (WAIS-III), Digit-Symbol Coding [31] words
and colours score from the Stroop Test [32] and Trail
Making Test A [30].
Blood collection
Blood samples were withdrawn from all study partici-
pants at baseline (study entry) in the morning (atapproximately 8:30 a.m. after fasting overnight) by
venipuncture into vacuum tubes containing ethylene di-
amine tetraacetic acid (EDTA). Plasma was prepared by
centrifugation at 300 x g for 10 min and the resulting
supernatant was removed and then frozen at −80°C, as
described previously [20]. Patient blood was also col-
lected at 6 months after the acute episode on the same
day as the cognitive assessments and plasma prepared as
described above.
BDNF sandwich enzyme-linked ImmunoSorbent assay
(ELISA)
Plasma BDNF levels were measured using a BDNF Sand-
wich ELISA Kit, according to the manufacturer’s instruc-
tions (Millipore, USA, Cat. No. CYT306). Briefly, diluted
plasma samples (diluted 1:100) and serial dilutions of
the BDNF standards (ranging from 7.8 to 500 pg/ml
BDNF) were incubated for 24 hours in 96-well immuno-
assay plates pre-coated with mouse anti-human BDNF
monoclonal antibody. The plates were then washed and
a biotinylated mouse anti-human BDNF monoclonal
antibody (diluted 1:1000 with diluent) was added to each
well and incubated for 3 hours at room temperature.
After washing, a streptavidin-enzyme conjugate (diluted
1:1000) was added and incubated at room temperature
for 1 hour. After further washing, a substrate solution
was added to the plates to initiate a reaction, which was
stopped after 15 min by adding the stop solution (HCl).
The amount of BDNF was determined immediately by
measuring absorbance at 450 nm using a microplate
reader. The standard curve demonstrated a direct rela-
tionship between optical density and BDNF concentration.
Statistical analysis
Statistical analyses were performed using SPSS version
15.0. The sociodemographic characteristics of the sample
were described using means ± standard deviations (SD)
or frequencies, depending on the nature of the variable.
Cognitive performance comparisons between patients
and controls were analysed using student t tests because
the variances were homogeneous. Bonferroni corrections
were applied and the stated level of significance was P =
0.01 for memory and learning, P = 0.005 for executive
function and working memory, P = 0.012 for processing
speed and attention, and P = 0.025 for intelligence. We
performed multivariate regression analyses with the cog-
nition domains and BDNF levels, which controlled for
the effects of the following variables: IQ, negative symp-
toms, use of typical/atypical antipsychotics, alcohol
abuse, tobacco use/dependence and drugs use/abuse.
We also controlled the association for the possible con-
founding effects of sex and age. Associations between
cognitive performance, plasma BDNF levels and factors
that could influence the results were assessed using
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that were significant in these analyses were introduced
as independent variables in the multivariate regression
analyses, with the cognitive dimensions as dependent
variables.Results
Sociodemographic characteristics
Table 1 summarises the sociodemographic characteristics
of the patient sample (n = 45) and healthy controls (n =
45). The two groups were similar, with a median age of
24 years, 55.6% of participants were male, and the major-
ity were single and lived with their parents or guardians
(77.3% patients vs. 60% controls). Also, there was no sig-
nificant difference in the years of education between the
patient and control groups (Table 1). The majority of
patients (88.8%) were antipsychotic treatment-naive at
baseline. Immediately upon being hospitalised, all except
one patient received antipsychotics: 22.2% were prescribed
a typical antipsychotic (the majority received haloperidol,
dose range 10–20 mg/day), 60% were prescribed an atyp-
ical antipsychotic (the majority received risperidone, dose
range 6–9 mg/day, or olanzapine, dose range 10–20 mg/
day), and 15.5% were prescribed a combination of atypical
antipsychotics and mood stabilizers. Antipsychotic pre-
scription remained stable over the subsequent 6-month
period, with only small changes in dose.
Tobacco was smoked by 64.4% of the patient group
but only 17.8% of the control group. The frequency of
alcohol use/abuse was higher in the patient group
(66.7%) than in the control group (35.6%). Overall,
48.9% of patients used or abused cannabis while only
6.7% of the control subjects used/abused cannabis. In
addition, 28.9% of the patient group reported sporadic
use of other drugs, such as cocaine, “ecstasy” (methyle-
nedioxymethamphetamine, MDMA) and amphetamines,
whereas none of the healthy matched controls reported
use of other drugs.Cognitive performance
Table 2 summarises the mean cognitive performance
scores for patients at 6 months after the acute episode
and for healthy controls in the following domains: mem-
ory and learning, executive functions, working memory,
processing speed, attention and intelligence. In the ma-
jority of these domains, the cognitive performance of
patients was significantly worse compared with the
healthy controls. There was a memory deficit in patients
at 6 months follow-up after their first psychotic episode
as shown by mean scores of around 8 for the memory
tests (except learning curve). The memory performance
of the control group was higher than that of the patient
group.The executive function scores of the patient group
were significantly different from the control group, with
the exception of number of words and digits (Table 2).
In addition, the scores for verbal fluency, digits and
Stroop interference in the patient group were within the
normal range and did not differ significantly from the
control group (after Bonferroni correction). All scores
for the patients’ processing speed and attention were sig-
nificantly different from those in the healthy controls.
Although the intelligence scale (vocabulary and similar-
ities) scores were significantly different between patients
and controls, all these scores were within the normal
range of 8–12.
Plasma BDNF levels and cognitive subtests
Baseline plasma BDNF levels (ng/ml) were significantly
lower in the patient group compared with the control
group (patients 6.09 ± 3.70; controls 9.19 ± 4.21; t = 3.25;
P = 0.002). There was no significant difference in plasma
BDNF levels between patients at 6 months (mean = 8.17,
SD = 3.85) and controls (mean = 9.19, SD = 4.21; t = 1.07;
P = 0.290).
We observed a significant positive association between
plasma BDNF levels at 6 months after first hospitalisa-
tion and several of the cognitive domains (Table 3): ab-
stract reasoning and processing speed (Wechsler Adult
Intelligence Scale: Similarities, Digit-Symbol Coding),
and learning capacity and delayed memory (Wechsler
Memory Scale: Logical Memory Learning Curve, Verbal
Paired Associates I Learning Curve and Verbal Paired
Associates II). Moreover, there was also a significant
positive correlation between the performance of the Vo-
cabulary test (IQ) and the results in Similarities, Digit-
Symbol Coding and Verbal Paired Associates II (Table 3).
Additionally, negative symptoms measured by the
PANSS had a significant negative correlation with Simi-
larities, but was not significantly associated with any of
the other cognitive subtests. Tobacco use in patients was
not significantly associated with cognition, although
there was a trend of association with Digit-Symbol Cod-
ing (P = 0.050) and Learning Curve of Logical Memory
(P = 0.054).
In the healthy control group, there was no significant
association between plasma BDNF levels and any of the
cognitive test results (Table 4). However, simple regres-
sion analyses found a significant positive correlation
between Similarities performance and the Wechsler
Vocabulary scale (IQ), Verbal Paired Associates II and
tobacco use, and between Learning Curve of Logical
Memory and age. In addition, the Digit-Symbol Coding
results were predicted by the Vocabulary Scale (IQ),
tobacco use and alcohol use (Table 4).
Finally, we performed one multivariate regression ana-
lysis for each of the five cognitive subtests (Similarities,
Table 2 Mean scores (SD) for the cognitive tests in patients at 6 months after acute episode and in healthy
control subjects
Cognitive task Controls Patients Confidence t* P value
(n = 45) (n = 45) interval
Memory and learning
Immediate Logical memory 10.50 (2.81) 8.05 (3.06) 0.622-0.896 3.635 0.001*
Learning Curve 11.39 (2.76) 10.66 (2.90) 0.772-1.072 1.134 0.260
Immediate Verbal Paired Associates 10.84 (3.80) 7.68 (3.22) 0.679-0.904 3.860 <0.001*
Delayed Logical memory 10.74 (3.45) 7.87 (3.48) 0.671-0.912 3.610 0.001*
Delayed Verbal Paired Associates 9.87 (2.04) 8.26 (2.43) 0.577-0.907 3.114 0.003*
Executive function/Working memory
Trail Making B 62.33 (23.36) 95.27 (42.87) 1.016-1.053 −4.525 <0.001*
WAIS-III Letter-Number Span 11.22 (3.42) 8.02 (2.99) 0.616-0.856 4.695 <0.001*
WAIS-III Digits 10.38 (3.06) 8.89 (2.60) 0.710-0.968 2.488 0.015
WCST Number of errors 102.93 (16.51) 86.20 (22.64) 0.936-0.982 3.975 <0.001*
WCST Perseverative errors 102.93 (16.51) 89.50 (27.82) 0.959-0.994 2.745 0.007
WCST% Conceptual level R 102.88 (15.73) 86.14 (22.64) 0.938-0.984 3.683 <0.001*
Number of words FAS 14.16 (3.51) 12.44 (4.62) 0.810-1.002 1.988 0.05
Category fluency (animals) 22.69 (5.83) 18.16 (5.69) 0.795-0.945 3.729 <0.001*
Stroop interference 54.80 (8.09) 50.36 (8.05) 0.875-0.987 2.596 0.011
Processing speed and attention
Trail Making A 35.00 (16.51) 47.29 (17.45) 1.016-1.079 −3.432 0.001*
WAIS-III Digit-Symbol Coding 10.24 (3.72) 7.52 (3.45) 0.698-0.932 3.282 0.002*
Stroop words 49.95 (7.59) 44.47 (9.49) 0.873-0.978 3.008 0.003*
Stroop colours 45.77 (6.67) 39.40 (8.62) 0.841-0.955 3.894 <0.001*
Intelligence
WAIS-III Vocabulary 10.95 (2.19) 9.15 (3.02) 0.633-0.920 3.134 0.002*
WAIS-III Similarities 10.76 (2.36) 8.55 (2.48) 0.547-0.850 3.978 <0.001*
* Student’s t-test statistic.
Standard ranges: memory and learning: low ≤ 7, normal = 8-12, high ≥ 13; WAIS-III: low ≤ 7, normal = 8-12, high ≥ 13; Stroop: low ≤ 39, normal = 40-60, high ≥ 61;
WCST (Wisconsin Card Sorting Test): deterioration < 106; no deterioration > 107; Trail Making A: low ≤ 39; normal ≥ 40; Trail Making B: low ≤ 91; normal ≥ 92; FAS
(Fluency Assessment Scale): low ≤ 9; normal ≥ 10.
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Associates I, and Verbal Paired Associates II) including
as independent variables those variables that were
significant in the simple regression analyses. The Simi-
larities variable model (r2 = 0.491) was predicted by the
BDNF levels (ß = 0.349, P = 0.023) and IQ (ß = 0.663,
P < 0.001), while negative symptoms measured by the
PANSS negative scale were no longer significant. The
performance of Digit-Symbol Coding (r2 = 0.328) was
significantly associated with BDNF levels (ß = 0.325, P =
0.037) and IQ (ß = 0.467, P = 0.004). In the Learning
Curve, Logical Memory (r2 = 0.291) and Verbal Paired
Associates I (r2 = 0.123) were both significantly asso-
ciated with BDNF levels (ß = 0.559, P = 0.001 and ß =
0.388, P = 0.025, respectively). Finally, delayed memory
assessed using the Verbal Paired Associates II (r2 =
0.284) was significantly associated with BDNF levels
(ß = 0.322, P = 0.041) and IQ (ß = 0.432, P = 0.008).Discussion
The results of the present clinical study show that plasma
BDNF levels at 6 months after first hospitalisation for first
episode psychosis (when patients have recovered from the
acute episode) are positively associated with several cogni-
tive domains. That is, cognitive performance is better in
patients with higher BDNF levels. Specifically, we found
positive associations between plasma BDNF levels and
learning capacity (Logical Memory and Verbal Paired
Associates I Learning Curve), verbal delayed memory
(Verbal Paired Associates II), abstract verbal reasoning
(Similarities) and processing speed (Digit-Symbol Coding)
in patients. In contrast, an association between plasma
BDNF levels and cognition was not seen in healthy con-
trol subjects. Similarly, some studies have found an associ-
ation between immediate memory and BDNF levels in
schizophrenic patients but not in healthy controls [34]. A
possible explanation for our findings is that healthy
Table 3 Simple linear regression analyses results of the association between cognition and plasma BDNF levels,










r2 ß (P) r2 ß (P) r2 ß (P) r2 ß (P) r2 ß (P)
BDNF plasma levels 0.194 0.468 0.130 0.397 0.291 0.559 0.140 0.409 0.118 0.382
(0.006) (0.024) (0.001) (0.018) (0.028)
Pharmacological treatment −0.027 0.025 −0.025 −0.056 0.011 0.193 −0.002 −0.157 0.002 −0.117
(0.883) (0.743) (0.245) (0.346) (0.305)
Wechsler Vocabulary (IQ) 0.432 0.669 0.262 0.531 −0.028 −0.015 0.007 0.183 0.224 0.495
(0.000) (0.001) (0.928) (0.270) (0.002)
Negative symptoms (PANSS N) 0.257 −0.530 0.081 −0.335 −0.033 −0.014 0.038 −0.264 0.052 −0.288
(0.002) (0.066) (0.939) (0.145) (0.110)
Tobacco use 0.034 0.246 0.080 0.325 0.074 0.315 −0.011 0.127 1.046 0.120
(0.136) (0.050) (0.054) (0.449) (0.302)
Alcohol use −0.020 0.111 −0.020 −1.112 0.001 0.179 0.053 0.287 −0.017 0.120
(0.538) (0.541) (0.320) (0.105) (0.505)
Cannabis use −0.021 −0.102 −0.017 −0.121 −0.027 0.067 0.001 0.178 −0.027 0.064
(0.568) (0.503) (0.706) (0.314) (0.719)
Other drugs use 0.025 0.083 0.059 −0.299 −0.018 0.117 −0.013 0.137 −0.032 −0.002
(0.646) (0.097) (0.518) (0.448) (0.993)
r2: Adjusted R-square; ß: Standardized correlation coefficient.
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sufficient cognitive reserve to compensate for other pos-
sible deficits present in patients with low BDNF levels; i.e.,
the brains of individuals with higher BDNF have a greater
resistance to damage. Higher cognitive reserve has been
shown to have a protective effect against dementia,
schizophrenia and depression [35,36]. In the New Zealand
Dunedin cohort, lower IQ was found to be a risk factor
for the development of schizophrenia spectrum disorders
[37]. In our sample, the healthy volunteer group had a
higher IQ than the patient group and performed better in
almost all of the cognitive tests. In both groups, IQ was
positively associated with abstract thinking and processing
speed.
Our results that patients with higher BDNF levels have
better cognitive performance suggest that plasma BDNF
levels could be used as a biological marker of cognition
in patients with a first psychotic episode. Cognitive per-
formance is an important clinical variable associated
with prognosis in severe mental illness [3]. The nature
of the relationship is unclear but, based on previous
studies [38], we can hypothesize that lower BDNF func-
tioning in the brain (e.g. during an acute episode of
psychosis) can lead to cognitive impairment and could
contribute towards the differences in cognition observed
between different patients and between patients and
healthy subjects. Other investigations have foundpositive relationships between BDNF levels and cogni-
tion in patients with diseases that result in cognitive im-
pairment. One study found an association between
maintained increases in serum BDNF levels and
improved cognition in patients with schizophrenia, and
suggested that serum BDNF levels could be used as a
biological marker of cognitive improvement [38]. An-
other study found a positive correlation between serum
BDNF levels and hippocampal volumes, which could ex-
plain the relationship between the BDNF and memory
[8]. Moreover, BDNF levels could change during treat-
ment with some medications. In patients with early Alz-
heimer’s disease, up-regulation of BDNF with lithium
treatment has been associated with increases in cognitive
performance [39]. In addition, some studies in rats have
shown that BDNF mediates exercise-induced enhance-
ments in learning and memory [40].
Plasma BDNF levels vary over time in psychosis [20]
and schizophrenia [18], as demonstrated in the present
study, where mean BDNF levels were lower during the
acute first episode of psychosis and increased to normal
levels (comparable to those in healthy subjects) after
6 months of naturalistic treatment when patients were
in remission. Plasma BDNF levels have a significant
negative correlation with positive symptoms at psychosis
onset [41]. A recent study found that after 6 weeks of
antipsychotic treatment, BDNF levels did not increase in
Table 4 Simple linear regression analysis results of the association between cognition and plasma BDNF levels, IQ,









r2 ß (P) r2 ß (P) r2 ß (P) r2 ß (P) r2 ß (P)
BDNF plasma levels −0.026 0.091 −0.011 −0.150 −0.034 −0.012 −0.034 0.010 0.035 −0.260
(0.626) (0.421) (0.947) (0.957) (0.159)
Wechsler Vocabulary (IQ) 0.332 0.591 0.137 0.401 −0.027 0.030 −0.014 −0.115 −0.026 0.044
(0.000) (0.013) (0.859) (0.493) (0.791)
Tobacco use 0.021 0.218 0.086 −0.332 −0.027 −0.027 −0.013 0.122 0.107 0.363
(0.188) (0.042) (0.870) (0.466) (0.025)
Alcohol use −0.052 0.060 0.166 −0.458 −0.043 0.108 −0.042 0.114 −0.033 0.148
(0.801) (0.042) (0.651) (0.631) (0.534)
r2: Adjusted R-square; ß: Standardized correlation coefficient.
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pine, but increased significantly in the subgroup treated
with olanzapine [7]. Another study found a significant
increase plasma BDNF levels during the first 6 months
of follow-up after olanzapine treatment [15]. Recently,
low serum levels of BDNF were found to be a state mar-
ker of depression that normalise during remission [42].
Our finding of a positive association between BDNF
levels and cognition in FEP patients who have recovered
from an acute episode of psychosis may be partly due to
the effects of pharmacotherapy on BDNF levels in these
patients.
In contrast to the variability of BDNF levels, cognitive
impairments are more stable in patients with psychosis
[43]. The observed associations between BDNF levels
and cognition were significant when patients had recov-
ered from their positive symptoms. These results raise
the question of whether plasma BDNF levels may be
used a possible marker beyond the acute clinical state.
The results of the multivariate regression models show
that plasma BDNF levels are independently associated
with several cognitive domains (learning capacity, verbal
delayed memory, abstract verbal reasoning and processing
speed); that is, patients with lower BDNF levels have a
worse cognitive performance independent of premorbid
IQ. However, our study shows that IQ is also an important
independent factor associated with some cognitive
domains (processing speed and delayed memory), as has
been reported previously [44,45]. Cognitive performance
has also been associated with negative symptoms [46]. We
found that negative symptoms were inversely related to
the Similarities subtest of the WAIS. However, the associ-
ation was no longer significant when PANSS negative
symptoms were introduced in the multivariate regression
model together with BDNF and IQ.
This study has some limitations. The patients received
pharmacological treatment in a naturalistic setting but
we cannot analyse the possible differential effects ofantipsychotics on BDNF because the sample is not large
enough. In addition, other biological factors, such as oxi-
dative stress [47] and environmental factors not mea-
sured in this study, could be associated with cognition.
The small sample size can limit the statistical power.
Nevertheless, the sample was large enough to suggest
that BDNF and cognitive performance are associated,
and that plasma BDNF levels after clinical stabilisation
could be used as a biological marker of cognition in
psychotic disorders.Conclusion
The cognitive performance of FEP patients is signifi-
cantly lower than that of healthy control subjects across
several cognitive domains. Plasma BDNF levels are asso-
ciated with cognitive impairment in FEP patient but not
in healthy controls. Cognitive performance is better in
patients with higher BDNF levels when assessed after
clinical stabilisation.
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